Table 3.

Regression analyses for SF-36v2 scores in tiopronin-treated patients

	Physical functioning		Role physical		Bodily pain		General health		Vitality		Social functioning		Role emotional		Mental health
	B	p	B	p	B	p	B	p	B	p	B	p	B	p	B	p
Age	− 0.13	0.001	− 0.061	0.141	− 0.029	0.474	0.06	0.154	0.08	0.046	0.03	0.440	0.03	0.501	0.11	0.005
Gender	− 2.391	0.034	− 3.83	0.002	− 2.46	0.045	− 3.082	0.008	− 3.61	0.002	− 5.37	0.00	− 4.71	0.00	− 3.65	0.002
Last stone event in groups	1.78	0.015	3.82	0.00	5.69	0.00	3.770	0.00	4.18	0.00	4.51	0.00	2.82	0.001	2.42	0.001
Comorbidities	− 2.26	0.00	− 2.58	0.00	− 2.23	0.00	− 3.007	0.00	− 2.682	0.00	− 2.90	0.00	− 2.36	0.00	− 2.55	0.000
R2	0.272		0.318		0.343		0.394		0.384		0.418		0.276		0.333
Adjusted R2	0.259		0.306		0.331		0.382		0.373		0.407		0.262		0.320
F	20.300		25.14		27.97		35.18		33.31		38.49		20.49		26.53
Significance of F	0.00		0.00		0.00		0.00		0.00		0.00		0.00		0.00
N	277		275		274		277		273		274		275		272

Stone event groups: 1 = stone event within 30 days; 2 = stone event within 31–365 days, 3 = stone event > 1 year

SF-36v2 short form-36, version 2